Drug Type Small molecule drug |
Synonyms + [3] |
Target |
Mechanism GnRHR antagonists(Gonadotropin-releasing hormone receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC36H35F7N4O6 |
InChIKeyLJPSGSMPGVITHK-MHZLTWQESA-N |
CAS Registry1454272-94-6 |
Start Date15 Aug 2024 |
Sponsor / Collaborator |
Start Date01 Nov 2023 |
Sponsor / Collaborator |
Start Date19 Aug 2021 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Endometriosis | Phase 2 | IT | 19 Aug 2021 | |
Endometriosis | Phase 2 | CZ | 19 Aug 2021 | |
Endometriosis | Phase 2 | PL | 19 Aug 2021 | |
Endometriosis | Phase 2 | UA | 19 Aug 2021 | |
Endometriosis | Phase 2 | RU | 19 Aug 2021 | |
Leiomyoma | Phase 2 | KR | - | |
Leiomyoma | Phase 2 | KR | - | |
Uterine Fibroids | Phase 1 | CN | 12 Sep 2023 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
NCT05138562 (PRNewswire) Manual | Phase 2 | 86 | Merigolix 120 mg | (znvmsfqcyx) = zotezdbium vcnjuhphng (fxqbsypaci ) Met | Positive | 08 May 2024 | |
Merigolix 240 mg | (znvmsfqcyx) = gqbbzsuvta vcnjuhphng (fxqbsypaci ) Met |